Elamipretide (SS-31): Mitochondrial Peptide Science Explained
Elamipretide (SS-31) targets cardiolipin on the inner mitochondrial membrane. Here is what the clinical trial evidence actually shows, and what to track.
Elamipretide (SS-31): What the Mitochondrial Peptide Research Actually Shows **Elamipretide** (also called SS-31, MTP-131, or by the brand name Forzinity) is one of the most rigorously studied mitochondria-targeted compounds in clinical research today. If you follow longevity science, the peptide has almost certainly crossed your feed. In September 2025, it became the first drug approved by the FDA for Barth syndrome, a rare and life-limiting mitochondrial disease. But what does the broader body of evidence actually show, and what does the mixed trial record mean for those tracking mitochondrial health? This post breaks down the mechanism, the clinical trial landscape (including Phase 3 failures), the emerging aging research, and the recovery markers worth logging if you are following this space. MyProtocolStack is a tracking and education tool. Nothing here constitutes medical advice. Always consult a qualified healthcare professional before using or discontinuing any compound.
What Is Elamipretide and How Does It Work?
Elamipretide is a synthetic tetrapeptide. Its structure gives it a unique property: it concentrates selectively in the inner mitochondrial membrane without requiring the electrical gradient that other mitochondria-targeted molecules depend on.
Once at the inner membrane, elamipretide binds cardiolipin, a phospholipid almost exclusively found there. Cardiolipin is not a passive structural molecule. It plays an active role in organizing the electron transport chain complexes and stabilizing the cristae architecture where ATP synthesis occurs. Researchers have found that cardiolipin composition and abundance decline with age and in disease states, impairing bioenergetic efficiency.
By binding cardiolipin, elamipretide is proposed to:
A 2025 review published in the International Journal of Molecular Sciences summarized that the compound works by "stabilizing mitochondrial cristae structure, reducing oxidative stress, and enhancing adenosine triphosphate (ATP) production" across a range of preclinical and clinical contexts.
The Clinical Trial Landscape: Honest Evidence Tiers
### TAZPOWER: Barth Syndrome and the Path to FDA Approval
Barth syndrome is an X-linked mitochondrial disease caused by mutations in the gene encoding tafazzin, an enzyme required for cardiolipin remodeling. Because cardiolipin is the direct target of elamipretide, Barth syndrome was a scientifically logical fit.
The TAZPOWER study was a Phase 2/3 randomized, double-blind, crossover trial. The 12-week blinded phase did not produce statistically significant differences on the primary clinical endpoints, a finding partly attributed to the extremely small eligible patient population limiting statistical power.
The 168-week open-label extension (OLE) told a more compelling story. Published findings showed cumulative improvement of roughly 96 meters on the 6-minute walk test by week 168, meaningful improvements in fatigue scores, and positive trends in cardiac volume measurements. On the basis of improved knee muscle strength data, the FDA granted accelerated approval to elamipretide HCl (Forzinity) in September 2025 for Barth syndrome in patients weighing at least 30 kg. Forzinity is the first approved therapy for Barth syndrome.
### MMPOWER: Primary Mitochondrial Myopathy
Primary mitochondrial myopathy (PMM) refers to a group of genetic disorders disrupting the mitochondrial respiratory chain. Phase 2 work (MMPOWER-2) was encouraging: patients treated with elamipretide reported significantly less fatigue compared with placebo.
MMPOWER-3, the pivotal Phase 3 study, did not replicate those results. It failed to meet its co-primary endpoints of improvement in 6-minute walk test distance and Total Fatigue Score versus placebo. Published in Neurology, the outcome was a setback, though researchers noted insights into PMM disease heterogeneity that may inform future trial design.
### ReCLAIM: Dry AMD and Geographic Atrophy
Mitochondrial dysfunction in retinal pigment epithelium cells is implicated in age-related macular degeneration. The ReCLAIM-2 study was a Phase 2, randomized, placebo-controlled trial evaluating elamipretide for 48 weeks in patients with noncentral geographic atrophy. Results were published in Ophthalmology Science. No FDA approval for this indication has been granted.
Evidence Summary Table
|---|---|---|---|---|
The honest reading: elamipretide has produced FDA approval in one rare disease, mixed signals in another serious indication, and ongoing investigation in others. It is not a broadly approved compound, and the evidence for use outside approved indications is still being developed in clinical settings.
Preclinical Aging Research: What Animal Models Show
While human trial data is mixed, the preclinical literature on elamipretide and aging is substantial enough to anchor serious scientific interest.
A 2018 study in Free Radical Biology and Medicine showed that 8-week SS-31 treatment reversed age-related decline in maximum mitochondrial ATP production in aged mice, restored redox homeostasis in skeletal muscle, and increased treadmill endurance.
A 2020 study in eLife demonstrated that late-life SS-31 treatment substantially reversed cardiac diastolic dysfunction in old mice by normalizing proton leak and reducing mitochondrial ROS.
A 2025 study in Aging Cell added nuance: elamipretide improved cardiac and skeletal muscle function in aging mice without producing detectable changes in epigenetic or transcriptomic age markers. This suggests its effects operate through acute bioenergetic improvement rather than fundamental reprogramming of the aging process, at least in the animal models studied.
These findings do not translate directly to humans, and none of these models involved healthy adults seeking longevity optimization. Researchers who study mitochondrial aging consider elamipretide a scientifically credible probe of the cardiolipin-mitochondria axis. Clinical translation remains a work in progress.
What to Track: Mitochondrial and Recovery Markers
For those following the elamipretide research or tracking mitochondrial health more broadly, the functional readouts studied in trials map reasonably well to metrics that wearables and periodic lab work can approximate. MyProtocolStack imports wearable recovery data and lets you log these alongside protocol notes from your provider.
### Recovery and Aerobic Capacity
### Biomarkers Worth Discussing with Your Provider
For a broader look at peptides studied in the recovery and longevity space, explore the [peptides hub](/peptides). Related compounds researchers study in mitochondrial and metabolic contexts include [MOTS-c](/peptides/mots-c), [Epithalon](/peptides/epithalon), and [Tesamorelin](/peptides/tesamorelin). The full [biomarkers hub](/biomarkers) surfaces labs commonly tracked alongside these protocols.
The Longevity Angle: Why This Peptide Gets Attention
Mitochondrial dysfunction is increasingly recognized as a central mechanism of biological aging, not merely a downstream consequence. Cardiolipin remodeling specifically declines with age across tissues. A compound that appears to stabilize the inner membrane architecture where ATP synthesis occurs is therefore mechanistically compelling for aging researchers, even if the primary approved indication is a rare disease.
What this means for healthy individuals interested in mitochondrial optimization is, frankly, unknown. There are no randomized controlled trials of elamipretide in healthy aging adults. Researchers studying the compound emphasize that clinical data comes from disease populations with documented mitochondrial impairment. Discuss any interest in investigational compounds with a licensed healthcare provider who understands your full health picture.
Frequently Asked Questions
What is elamipretide (SS-31)?
Elamipretide, also known as SS-31 or MTP-131, is a synthetic tetrapeptide developed by Stealth BioTherapeutics. Researchers designed it to selectively bind cardiolipin on the inner mitochondrial membrane with the goal of stabilizing mitochondrial structure and improving energy production. It received FDA accelerated approval under the brand name Forzinity for Barth syndrome in September 2025.
Is elamipretide FDA approved?
As of September 2025, elamipretide HCl (Forzinity) holds FDA accelerated approval for Barth syndrome in patients weighing at least 30 kg. It is not approved for primary mitochondrial myopathy, dry AMD, or general longevity use. The accelerated approval pathway means a confirmatory trial is still required.
What did the TAZPOWER trial find?
TAZPOWER did not meet primary endpoints in the 12-week blinded phase. The 168-week open-label extension showed cumulative gains in walk test performance (approximately 96 meters), improved fatigue scores, and positive trends in cardiac volumes. These long-term results, along with knee muscle strength data, supported the FDA's accelerated approval decision.
What happened in MMPOWER-3?
MMPOWER-3 was a Phase 3 trial in primary mitochondrial myopathy that failed to meet its co-primary endpoints (6-minute walk test and Total Fatigue Score) versus placebo. Earlier Phase 2 data had been more encouraging. The discordance is a reminder that smaller, shorter trials can overestimate treatment effects.
What recovery markers are most relevant to follow?
Clinical elamipretide research focuses on 6-minute walk test performance, fatigue scores, and cardiac function. Consumer proxies include HRV (trackable via most modern wearables), VO2 max estimates, resting heart rate, and daily subjective energy logs. Discuss lab-based markers such as lactate, hs-CRP, and IGF-1 with your provider.
Sources
1. Tung C, et al. "Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential." International Journal of Molecular Sciences, 2025.
2. Campbell MD, et al. "Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice." Free Radical Biology and Medicine, 2018.
3. Chiao YA, et al. "Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice." eLife, 2020.
4. Mitchell WK, et al. "Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age." Aging Cell, 2025.
5. Karaa A, et al. "Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy." Neurology, 2024.
6. Stealth BioTherapeutics. "Long-term efficacy and safety of elamipretide in Barth syndrome: 168-week open-label extension of TAZPOWER." Genetics in Medicine, 2024.
7. Stealth BioTherapeutics. "FDA Accelerated Approval of FORZINITY (elamipretide HCl), the First Therapy for Barth Syndrome." September 2025.
8. Karaa A, et al. "A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy." Journal of Cachexia, Sarcopenia and Muscle, 2020.
9. ReCLAIM-2 Study. Ophthalmology Science, 2024.
10. Fight Aging. "FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31." October 2025.
*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, adjusting, or stopping any compound or protocol. Ready to start logging your recovery and biomarker data? [Create your free account](/auth/login?mode=signup) and begin building your personal health timeline.*
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.
Start Free →